Relationship between COVID-19 and antimicrobial resistance

Abstract

Objective: Bacterial and fungal infections, antimicrobial resistance (AMR) results of bacterial agents, and the effect of the pandemic on AMR were evaluated in hospitalized COVID-19 patients. In addition, the detected AMR rates were compared with the AMR rates of the pre-pandemic period. Patients and Methods: The isolates grown in respiratory and blood samples of adult patients hospitalized with the diagnosis of COVID-19 between March 2020 and December 2020 were evaluated retrospectively. The same data in hospitalized patients before the pandemic, between March and December 2019, were evaluated retrospectively. Results: A total of 724 samples were included in the study. The superinfection rate was found to be 15.3%. The most frequently isolated microorganisms are; Acinetobacter baumannii (34.4%), Staphylococcus aureus (10.8%), Klebsiella pneumoniae (9.7%) and Pseudomonas aeruginosa (7.3%). The lowest resistance rates in Klebsiella pneumoniae isolates were found for aminoglycosides, in Acinetobacter baumannii isolates were found for trimethoprim-sulfamethoxazole, in Pseudomonas aeruginosa isolates were found for amikacin. When pre-pandemic and pandemic AMR rates were compared; a significant increase in amikacin resistance was detected only in Klebsiella pneumoniae isolates during the pandemic period (P:0.049). Conclusion: The data we have presented may help clinicians in the selection of antimicrobials for empirical therapy by revealing the effect of the pandemic on AMR.

Keywords

• Antimicrobial resistance
• Bacterial infection
• COVID-19
• Fungal infection

References

1. World Health Organization. Coronavirus Disease 2019 (COVID-19) Situation Report – 51. https://www.who.int/docs/ default-source/coronaviruse/situation-reports/20200311 – sitrep-51-covid 19.pdf?sfvrsn=1ba62e57_10. [Accessed on 30 January 2022]
2. Lai CC, Chen SY, Ko WC, Hsueh PR. Increased antimicrobial resistance during the COVID-19 pandemic. Int J Antimicrob Agents 2021; 57:106324. doi: 10.1016/j.ijantimicag.2021.106324.
3. Rizvi SG, Ahammad SZ. COVID-19 and antimicrobial resistance: A cross-study. Sci Total Environ 2022; 807(Pt 2):150873. doi: 10.1016/j.scitotenv.2021.150873.
4. Bengoechea JA, Bamford CG. SARS-CoV-2, bacterial coinfections, and AMR: the deadly trio in COVID-19? EMBO Mol Med 2020; 12:e12560. doi: 10.15252/emmm.202012560.
5. Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect 2020; 26:1622-9. doi: 10.1016/j.cmi.2020.07.016.
6. Clancy CJ, Nguyen MH. coronavirus disease 2019, superinfections, and antimicrobial development: What can we expect? Clin Infect Dis 2020; 71:2736-43. doi: 10.1093/cid/ ciaa524.
7. Klinik örnekten sonuç raporuna uygulama rehberi. Solunum sistemi örnekleri. Klinik Mikrobiyoloji Uzmanlık Derneği Yayınları 2015; 44-55. Available from: https://www.klimud. org/public/uploads/files/solunumsistemi – ornekleri.pdf [Accessed on 17 February 2022]
8. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) 2020. http://www.eucast.org/clinical_ breakpoints/ [Accessed on 17 February 2022]

9. Nori P, Cowman K, Chen V, et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. Infect Control Hosp Epidemiol 2021; 42:84-8. doi: 10.1017/ice.2020.368.
10. Zhu X, Ge Y, Wu T, et al. Co-infection with respiratory pathogens among COVID-2019 cases. Virus Res 2020; 285:198005. doi: 10.1016/j.virusres.2020.198005.
11. [11] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229):1054- 62. doi: 10.1016/S0140-6736(20)30566-3.
12. Rawson TM, Moore LSP, Zhu N, et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis 2020; 71:2459-68. doi: 10.1093/cid/ciaa530.
13. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and metaanalysis. J Infect 2020; 81(2):266-75. doi: 10.1016/j. jinf.2020.05.046.
14. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223):497-506. doi: 10.1016/S0140- 6736(20)30183-5.
15. Teich VD, Klajner S, Almeida FAS, et al. Epidemiologic and clinical features of patients with COVID-19 in Brazil. Einstein (Sao Paulo) 2020; 18:eAO6022. doi: 10.31744/einstein_ journal/2020ao6022.
16. Gerver SM, Guy R, Wilson K, et al. National surveillance of bacterial and fungal coinfection and secondary infection in COVID-19 patients in England: lessons from the first wave. Clin Microbiol Infect 2021; 27:1658-65. doi: 10.1016/j. cmi.2021.05.040
17. Silva DL, Lima CM, Magalhães VCR, et al. Fungal and bacterial coinfections increase mortality of severely ill COVID-19 patients. J Hosp Infect 2021; 113:145-54. doi: 10.1016/j. jhin.2021.04.001.
18. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8:475-81. doi: 10.1016/S2213- 2600(20)30079-5.
19. Dong X, Cao YY, Lu XX, et al. Eleven faces of coronavirus disease 2019. Allergy 2020; 75:1699-709. doi: 10.1111/ all.14289. Chen X, Zhao B, Qu Y, et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clin Infect Dis 2020; 71:1937-42. doi: 10.1093/cid/ ciaa449.
20. Zamora-Cintas MI, López DJ, Blanco AC, et al. Coinfections among hospitalized patients with covid-19 in the first pandemic wave. Diagn Microbiol Infect Dis 2021; 101:115416. doi: 10.1016/j.diagmicrobio.2021
21. Antinori S, Galimberti L, Milazzo L, Ridolfo AL. Bacterial and fungal infections among patients with SARS-CoV-2 pneumonia. Infez Med 2020; 28(suppl 1):29-36.
22. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223):507-13. doi: 10.1016/S0140-6736(20)30211-7.
23. Du Y, Tu L, Zhu P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan: a retrospective observational study. Am J Respir Crit Care Med 2020; 201:1372-9. doi: 10.1164/ rccm.202.003.0543OC.
24. Zavascki AP, Falci DR. Clinical Characteristics of Covid-19 in China. N Engl J Med 2020; 382(19):1859. doi: 10.1056/ NEJMc2005203.